Why the study?
Fulminant myocarditis and cardiogenic shock are rare in the post-acute phase of COVID-19, and the associated prognosis is very poor.
Does the use of ECMO and IABP improve survival and recovery in a patient with fulminant myocarditis and cardiogenic shock following COVID-19 infection?
Population
One 43-year-old man with fulminant myocarditis and cardiogenic shock after coronavirus infection
Design
Case report
Follow-up
Weekly after discharge
Authors
Loading...
Prompts vigilance for fulminant myocarditis in post-COVID shock; leaves open incidence and optimal management.
Does the use of ECMO and IABP improve survival and recovery in a patient with fulminant myocarditis and cardiogenic shock following COVID-19 infection?
ECMO and IABP can be life-saving interventions for patients presenting with fulminant myocarditis and cardiogenic shock following COVID-19 infection.
Yan et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: